Business Description
Glenmark Pharmaceuticals Ltd
ISIN : INE935A01035
Share Class Description:
NSE:GLENMARK: Ordinary SharesCompare
Compare
Traded in other countries / regions
GLENMARK.India IPO Date
2000-02-07Description
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.56 | |||||
| Debt-to-EBITDA | 7.14 | |||||
| Interest Coverage | 2.74 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.72 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7 | |||||
| 3-Year EBITDA Growth Rate | -1.1 | |||||
| 3-Year EPS without NRI Growth Rate | 3.3 | |||||
| 3-Year FCF Growth Rate | -66.3 | |||||
| 3-Year Book Growth Rate | 16 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.89 | |||||
| 9-Day RSI | 57.7 | |||||
| 14-Day RSI | 61.3 | |||||
| 6-1 Month Momentum % | 25.15 | |||||
| 12-1 Month Momentum % | 85.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.48 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 197.21 | |||||
| Days Sales Outstanding | 97.88 | |||||
| Days Payable | 154.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.24 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| 3-Year Dividend Growth Rate | 7.7 | |||||
| Forward Dividend Yield % | 0.24 | |||||
| 5-Year Yield-on-Cost % | 0.32 | |||||
| Shareholder Yield % | -2.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.33 | |||||
| Operating Margin % | 9.9 | |||||
| Net Margin % | -5.39 | |||||
| FCF Margin % | 0.13 | |||||
| ROE % | -7.52 | |||||
| ROA % | -3.72 | |||||
| ROIC % | 12.39 | |||||
| ROC (Joel Greenblatt) % | 1.16 | |||||
| ROCE % | 0.75 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 113.1 | |||||
| Shiller PE Ratio | 33.09 | |||||
| PEG Ratio | 45.24 | |||||
| PS Ratio | 2.21 | |||||
| PB Ratio | 3.14 | |||||
| Price-to-Tangible-Book | 4.24 | |||||
| Price-to-Free-Cash-Flow | 1657.43 | |||||
| Price-to-Operating-Cash-Flow | 46.74 | |||||
| EV-to-EBIT | 313.32 | |||||
| EV-to-EBITDA | 45.5 | |||||
| EV-to-Revenue | 2.5 | |||||
| EV-to-FCF | 1883.29 | |||||
| Price-to-Projected-FCF | 2.88 | |||||
| Price-to-DCF (Earnings Based) | 11.73 | |||||
| Price-to-DCF (FCF Based) | 178.36 | |||||
| Price-to-Median-PS-Value | 1.27 | |||||
| Price-to-Graham-Number | 2.61 | |||||
| Price-to-Net-Current-Asset-Value | 49.76 | |||||
| Earnings Yield (Greenblatt) % | 0.32 | |||||
| FCF Yield % | 0.06 | |||||
| Forward Rate of Return (Yacktman) % | 3.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Glenmark Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 132,089.84 | ||
| EPS (TTM) (₹) | -25.22 | ||
| Beta | 0.35 | ||
| Volatility % | 31.08 | ||
| 14-Day RSI | 61.3 | ||
| 14-Day ATR (₹) | 24.796242 | ||
| 20-Day SMA (₹) | 1014.695 | ||
| 12-1 Month Momentum % | 85.89 | ||
| 52-Week Range (₹) | 514.45 - 1070 | ||
| Shares Outstanding (Mil) | 282.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Glenmark Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Glenmark Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Glenmark Pharmaceuticals Ltd Frequently Asked Questions
What is Glenmark Pharmaceuticals Ltd(NSE:GLENMARK)'s stock price today?
The current price of NSE:GLENMARK is ₹1034.50. The 52 week high of NSE:GLENMARK is ₹1070.00 and 52 week low is ₹514.45.
When is next earnings date of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK)?
The next earnings date of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 2024-05-17 Est..
Does Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) pay dividends? If so, how much?
The Dividend Yield %  of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 0.24% (As of Today), Highest Dividend Payout Ratio of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) was 0.27. The lowest was 0.06. And the median was 0.08. The  Forward Dividend Yield % of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 0.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers